DE69716713D1 - Verfahren zur herstellung von d-threo-(r,r)-methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung - Google Patents

Verfahren zur herstellung von d-threo-(r,r)-methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung

Info

Publication number
DE69716713D1
DE69716713D1 DE69716713T DE69716713T DE69716713D1 DE 69716713 D1 DE69716713 D1 DE 69716713D1 DE 69716713 T DE69716713 T DE 69716713T DE 69716713 T DE69716713 T DE 69716713T DE 69716713 D1 DE69716713 D1 DE 69716713D1
Authority
DE
Germany
Prior art keywords
threo
methylphenidate
epimerization
producing
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69716713T
Other languages
English (en)
Other versions
DE69716713T2 (de
Inventor
Marianne Langston
Shahriari Zavareh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602174.6A external-priority patent/GB9602174D0/en
Priority claimed from GBGB9618836.2A external-priority patent/GB9618836D0/en
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Publication of DE69716713D1 publication Critical patent/DE69716713D1/de
Application granted granted Critical
Publication of DE69716713T2 publication Critical patent/DE69716713T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0004Crystallisation cooling by heat exchange
    • B01D9/0013Crystallisation cooling by heat exchange by indirect heat exchange
DE69716713T 1996-02-02 1997-01-31 Verfahren zur herstellung von d-threo-(r,r)-methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung Expired - Fee Related DE69716713T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9602174.6A GB9602174D0 (en) 1996-02-02 1996-02-02 Resolution/racemization process
GBGB9618836.2A GB9618836D0 (en) 1996-09-10 1996-09-10 Resolution/racemisation process
PCT/GB1997/000281 WO1997028124A1 (en) 1996-02-02 1997-01-31 Process for the preparation of d-threo-(r,r)-methyl phenidate and recycling of undesired enantiomers by epimerisation

Publications (2)

Publication Number Publication Date
DE69716713D1 true DE69716713D1 (de) 2002-12-05
DE69716713T2 DE69716713T2 (de) 2003-07-03

Family

ID=26308593

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716713T Expired - Fee Related DE69716713T2 (de) 1996-02-02 1997-01-31 Verfahren zur herstellung von d-threo-(r,r)-methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung

Country Status (16)

Country Link
US (1) US7164025B2 (de)
EP (1) EP0879228B1 (de)
JP (1) JP2000504008A (de)
KR (1) KR100453707B1 (de)
AT (1) ATE226940T1 (de)
AU (1) AU715183B2 (de)
CA (1) CA2243534C (de)
CZ (1) CZ292609B6 (de)
DE (1) DE69716713T2 (de)
DK (1) DK0879228T3 (de)
ES (1) ES2187753T3 (de)
HU (1) HUP9901658A3 (de)
MX (1) MX209701B (de)
PT (1) PT879228E (de)
SK (1) SK283553B6 (de)
WO (1) WO1997028124A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
GB9700912D0 (en) * 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
AU2005313887B2 (en) * 2004-12-09 2011-10-27 Celgene Corporation Treatment using D-threo methylphenidate
US7897777B2 (en) * 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK4011364T3 (da) 2011-03-23 2024-03-18 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
SU466229A1 (ru) * 1973-01-23 1975-04-05 Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты
US4254261A (en) * 1979-10-15 1981-03-03 Merck & Co., Inc. Dehydroabietylammonium salts of 6-oxo-2-piperidinecarboxylic acid
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6242464B1 (en) * 1996-01-22 2001-06-05 Chiroscience Limited Single isomer methylphenidate and resolution process
MX9805870A (de) * 1996-01-22 1999-01-31
GB9604943D0 (en) * 1996-03-08 1996-05-08 Chiroscience Ltd Resolution

Also Published As

Publication number Publication date
MX209701B (es) 2002-08-15
US20020032335A1 (en) 2002-03-14
CA2243534A1 (en) 1997-08-07
HUP9901658A3 (en) 1999-12-28
MX9806209A (es) 1998-10-31
AU1608297A (en) 1997-08-22
SK283553B6 (sk) 2003-09-11
CA2243534C (en) 2003-08-26
AU715183B2 (en) 2000-01-20
DK0879228T3 (da) 2003-03-03
SK97998A3 (en) 1999-01-11
EP0879228B1 (de) 2002-10-30
WO1997028124A1 (en) 1997-08-07
KR19990082186A (ko) 1999-11-25
DE69716713T2 (de) 2003-07-03
CZ227598A3 (cs) 1998-12-16
PT879228E (pt) 2003-01-31
KR100453707B1 (ko) 2005-01-25
EP0879228A1 (de) 1998-11-25
HUP9901658A2 (hu) 1999-09-28
ES2187753T3 (es) 2003-06-16
US7164025B2 (en) 2007-01-16
CZ292609B6 (cs) 2003-11-12
ATE226940T1 (de) 2002-11-15
JP2000504008A (ja) 2000-04-04

Similar Documents

Publication Publication Date Title
DE69716713D1 (de) Verfahren zur herstellung von d-threo-(r,r)-methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung
DE19681532T1 (de) Verfahren zur Herstellung von L-Glutaminsäure durch Fermentation
DE69630570D1 (de) Verfahren zur Herstellung von gestützten Membranen
DE69621491T2 (de) Verfahren zur Herstellung von Epsilon-Caprolactam
ATE81339T1 (de) Verfahren zur herstellung von zyklischen sulfaten.
DE69506020T2 (de) Verfahren zur Herstellung von Verbundmembranen
DE59609854D1 (de) Verfahren zur herstellung von verkappten polyarylenethern
DE69615660D1 (de) Verfahren zur herstellung von lactamen
DE59601745D1 (de) Verfahren zur Herstellung von 3-Aminomethyl-3,5,5-trimethylcyclohexylamin
DE59007171D1 (de) Verfahren zur herstellung von sclareolid.
DE3783568D1 (de) Verfahren zur herstellung von koks hoher qualitaet.
DE3863378D1 (de) Verfahren zur herstellung von koks hoher qualitaet.
ATE224871T1 (de) Verfahren zur herstellung von enantiomerenreinen azetdin-2-carbonsäuren
DE69610837D1 (de) Verfahren zur herstellung von laubholzelementen
DE69615063T2 (de) Verfahren zur herstellung von 4-methylen piperidinen
DE69010256T2 (de) Verfahren zur Herstellung von L-Ornithin durch Fermentation.
DE69611331T2 (de) Verfahren zur Herstellung von S-Phenyl-L-Cystein
DE69729631D1 (de) Verfahren zur herstellung von granisetron
DE69603243D1 (de) Verfahren zur Herstellung von Ethenylamiden
ATA196393A (de) Verfahren zur herstellung von spinnvliesen
DE69417061D1 (de) Verfahren zur herstellung von 2-chlor-1, 3-butadien pfropfcopolymeren
DE59505929D1 (de) Verfahren zur herstellung von epoxidgruppen enthaltenden organischen verbindungen
DE69606679D1 (de) Verfahren zur Herstellung von Aryl- und Vinylnitrilen
DE69126213T2 (de) Verfahren zur Herstellung von L-Alanin durch Fermentation
ATE193284T1 (de) Verfahren zur herstellung von benzylsubstituierten rhodaninederivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee